Atherosclerosis is the key underlying cause of cardiovascular disease (CVD). Atherosclerosis burden results from the accumulation of fat and cholesterol in the artery wall, leading to plaque that causes narrowing and hardening of the arteries, resulting in a loss of elasticity and function. The normal growth of atherosclerosis progression in many CVD patients is estimated to be 0.6% per year. ApoA-I production therapetuics are the only technologies to date to efficiently remove and regress atherosclerosis placque in in high risk CVD patients.
The image below illustrates the progression of atherosclerosis in CVD patients. As the disease progresses, the patient develops more severe coronary artery disease (CAD) resulting in increased risk of morbidity and death.
